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Abstract For patients with recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M
SCCHN), chemotherapy can prolong life and alleviate
symptoms. However, expected gains may be small, not
necessarily outweighing considerable toxicity and high
costs. Treatment choice is to a large extent dependent on
preferences of doctors and patients and data on these
choices are scarce. The purpose of this study is to obtain
real-world information on palliative systemic treatment and
costs of R/M SCCHN in the Netherlands. In six Dutch head
and neck treatment centers, data were collected on patient
and tumor characteristics, treatment patterns, disease pro-
gression, survival, adverse events, and resource use for
R/M SCCHN, between 2006 and 2013. 125 (14 %) out of
893 R/M SCCHN patients received palliative, non-trial
first-line systemic treatment, mainly platinum ? 5FU ?
cetuximab (32 %), other platinum-based combination
therapy (13 %), methotrexate monotherapy (27 %) and
capecitabine monotherapy (14 %). Median progression-
free survival and overall survival were 3.4 and 6.0 months,
respectively. 34 (27 %) patients experienced severe
adverse events. Mean total hospital costs ranged from
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€10,075 (±€9,891) (methotrexate monotherapy) to €39,459
(±€21,149) (platinum ? 5FU ? cetuximab). Primary cost
drivers were hospital stays and anticancer drug treatments.
Major health care utilization and costs are involved in
systemically treating R/M SCCHN patients with a limited
survival.
Keywords Carcinoma, squamous cell of head and neck 
Drug therapy  Costs and cost analysis
Abbreviations
5FU 5-Fluorouracil
AE Adverse event
CI Confidence interval
OS Overall survival
PDT Photodynamic therapy
PFS Progression-free survival
R/M
SCCHN
Recurrent and/or metastatic squamous cell
carcinoma of the head and neck
Introduction
In the Netherlands, 2,970 new cases of head and neck cancer
were diagnosed in 2011, approximately 1 per 6,000 inhab-
itants [1]. In up to 90 % of cases, this concerns squamous
cell carcinoma (SCCHN) [2]. Approximately 17 % of
SCCHN patients develop local tumor recurrence, 10 % of
patients develop regional tumor recurrence and 11 % pro-
gress to distant metastatic disease [3]. Distant metastases are
present at initial diagnosis in 1.8 % of patients [3]. Median
survival for patients with recurrent and/or metastatic
SCCHN (R/M SCCHN) is 6–9 months [4].
For some patients with loco-regional tumor recurrence,
surgery or radiotherapy may still cure the disease [5]. For
patients with non-curable loco-regional tumor recurrence
and patients with distant metastasis, palliation may be
offered by surgery, radiotherapy, photodynamic therapy
(PDT), or systemic treatment.
Radiotherapy may be used for loco-regional recurrent
tumors for radiation naı¨ve patients or when re-irradiation
is possible, typically with curative intent. Radiotherapy is
also the mainstay therapy to treat symptomatic bone
metastases. Systemic treatment may be used for the
palliative treatment of loco-regional recurrent disease
and/or distantly metastasized tumors. However, this
treatment is only considered in case of good performance
status and symptoms related to tumor growth. The pri-
mary aim of palliative chemotherapy is to alleviate
symptoms [6–8].
Active pharmaceutical agents registered for palliative
treatment in R/M SCCHN include the platinum compounds
(cisplatin and carboplatin), 5-fluorouracil (5FU), metho-
trexate, taxanes, bleomycin, and the monoclonal antibody
cetuximab [9]. They can be used as monotherapy or in
various combination regimens. No new compounds have
been identified in the past 5 years that demonstrate clinical
benefit in late stage clinical trials.
Historically, the usual first-line treatment for incurable
SCCHN has been combination chemotherapy with cisplatin
and 5FU. For clinically fit patients (performance score
0–1), international guidelines [9, 10] advise treatment with
platinum plus 5FU and cetuximab. Cetuximab, an EGFR
inhibitor added to platinum-5FU, increased overall survival
(median 10.1 vs. 7.4 months) and progression-free survival
(median 5.6 vs. 3.3 months) in a randomized controlled
phase III trial [11]. In November 2009, the scientific
committee (CieBOM) of the Dutch Association for Medi-
cal Oncology (NVMO) considered addition of cetuximab
to platinum-5FU to provide added therapeutic benefit for
clinically fit patients with R/M SCCHN [12].
Treatment with single agents may be offered to patients
who may not tolerate combination chemotherapy. For these
patients, Dutch guidelines recommend methotrexate
monotherapy. Although response percentages with metho-
trexate are lower than with platinum-5FU, overall survival
is similar [13].
Due to possible side effects and limited clinical benefit
of palliative systemic treatment in R/M SCCHN, treatment
choice is, to a large extent dependent on individual pref-
erences of doctors and their patients. In the Netherlands, a
lack of data exists on daily practice treatment patterns,
survival, adverse events and costs associated with man-
agement of R/M SCCHN. The aim of this study is to
provide insight into these outcome measures.
Methods
Data collection
More than 90 % of SCCHN patients are treated in one of
the head and neck treatment center [14], making head and
neck cancer care a highly centralized field of medicine in
the Netherlands. A retrospective, observational study was
conducted in six of a total of eight Dutch head and neck
treatment centers. Patients were identified from hospital
and pharmacy databases.
Medical charts were reviewed for patients diagnosed
with recurrent and/or metastatic (M?) squamous cell car-
cinoma of the head and neck (ICD-O C01–C14 and C30–
C32) between January 1, 2006 and July 3, 2013. Recur-
rence was defined as occurring within 2 cm of the original
tumor or lymph node site and within 5 years after primary
treatment of the initial, usually locally advanced, tumor.
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Data on all local and systemic treatments were recorded on
case report forms. For all study patients with at least one
line of palliative, non-trial systemic treatment, additional
patient and tumor characteristics, treatment details, resource
use and clinical outcomes were collected. Information on
treatment history was collected as well, but not used for
selection purposes. Patients who only received systemic
treatment in a clinical trial (n = 20), were excluded from
this extensive data collection since we aimed to present
real-world, daily practice treatment patterns and outcomes.
For patients treated in trials, management and therefore
resource use are usually guided by the trial protocol and,
therefore, not representative of daily practice.
Comorbidity was determined from medical records,
measured at baseline, using the updated Charlson comor-
bidity index. This index is valid for head and neck cancer
patients and predicts the 1-year in-hospital mortality based
on comorbidity [15, 16].
Clinical outcomes
Overall survival (OS) was defined as the duration between
date of treatment start (for the first palliative, systemic,
non-trial treatment) and date of death as registered in the
hospital record. For none of the patients a cause of death
other than head and neck cancer was registered. Progres-
sion-free survival (PFS) was defined as the time from
treatment start to disease progression, defined as: (1)
clinical or radiological progression of recurrent tumor and/
or distant metastases; (2) start of new treatment (with the
exception of treatment change due to toxicity); or (3) death,
whichever occurred first. A second primary tumor was not
classified as disease progression.
Adverse events (AEs) reported in the patient chart and
graded by a physician were recorded using the Common
Terminology Criteria for Adverse Events (case report form
based on CTC version 4.03). Adverse events for which no
grade was provided were recorded as severe adverse events if
they resulted in hospital admission or dose reduction, post-
ponement or change of treatment. No AE information was
derived from laboratory values or administered treatments.
Economic outcomes
Resource use included in-patient hospital days, day-care
hospital admissions, outpatient visits, drug usage, radio-
therapy, surgery and other invasive procedures, laboratory
diagnostics, imaging and pathology. Drug use other than
anti-cancer drugs, including treatments for adverse events,
was determined in a sub-selection of patients (n = 49), for
reasons of feasibility. Mean per patient treatment costs
were calculated combining resource use and unit costs,
derived from literature [17, 18] or official tariff lists.
Treatment costs were calculated from start of the respective
treatment onwards and include all subsequent resource use.
Costs are reported from the head and neck cancer center
perspective, in Euros. Unit costs are from 2013 or were
inflated to reflect the 2013 price level.
Analyses
Descriptive analyses were performed in IBM SPSS Sta-
tistics 21. The Kaplan–Meier method was used for survival
estimates.
Results
Treatment patterns
893 patients diagnosed with R/M SCCHN were identified
(Fig. 1), 20 of whom received systemic trial treatment
only. If patients received trial treatment at one point in time
but non-trial systemic treatment at another point in time,
these patients were included from start of the non-trial
treatment onwards (costs for trial treatment are set to €0
from a hospital perspective). 273 patients received no
antitumor treatment at all. 125 patients received at least one
line of palliative, non-trial systemic treatment and were
included in the study. Of these 125 study patients, 7
patients had metastasized SCCHN at primary diagnosis and
118 patients had R/M SCCHN after primary treatment. 93
study patients received non-trial systemic treatment as first
treatment after diagnosis of R/M SCCHN and 32 study
patients as second, third or fourth treatment.
Treatment characteristics
Multiple treatment modalities were administered (Fig. 1).
The most common first-line systemic treatment choices
(Table 1) were platinum ? 5FU ? cetuximab (n = 40,
32 %), other platinum-based combination therapies (n = 16,
13 %), methotrexate monotherapy (n = 34, 27 %) and
capecitabine monotherapy (n = 18, 14 %). An example of
an ‘‘other’’ first-line drug therapy was platinum monotherapy
(n = 9). Patients treated with first-line platinum-based
combination therapy without cetuximab received plati-
num ? fluorouracil (n = 6), cisplatin ? gemcitabine (n = 4),
platinum ? capecitabine (n = 2), and other platinum combi-
nation regimens (n = 4).
The percentage of patients treated with plati-
num ? 5FU ? cetuximab has increased steeply since 2010
(data not presented), following a positive decision on
reimbursement. In patients receiving platinum ? 5FU ?
cetuximab, 40 patients (32 %) received this combination in
first line, 4 (10 %) in second line, and 0 (0 %) in
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subsequent treatment lines. Other platinum-based combi-
nation therapies were administered to 16 patients (13 %) as
first-line therapy and to 1 (3 %) in second line. This regi-
men was administered as subsequent treatment to 1 patient
(14 %).
In the second systemic treatment line, methotrexate mono-
therapy was the most frequently prescribed drug regimen.
Patient and tumor characteristics
Patient and tumor characteristics are depicted in Table 2.
74 % of patients were male and the median age was 60.
Unfortunately, performance status was not routinely reg-
istered in all medical charts.
Survival measures
Table 3 shows PFS and OS per treatment group, from
treatment start onwards, without correction for baseline
characteristics. Median PFS and OS for the cohort studied
were 3.4 and 6.0 months, respectively. Due to heteroge-
neity, possibilities for matching on baseline characteris-
tics were limited and did not solve the issue of
confounding by indication. Therefore, survival estimates
should be interpreted as descriptive of the respective
treatment groups rather than measures of treatment effect.
Wide, overlapping confidence intervals reflect non-sig-
nificance of the survival differences, due to small size of
the treatment groups.
Adverse events
In the initial palliative treatment line, 34 patients (27 %)
experienced severe adverse events, defined as any adverse
events with registered record of: CTC AE grade C3,
treatment dose reduction(s), postponement or change of
Fig. 1 Treatment patterns for R/M SCCHN patients. The red numbers (color version online) represent eligible patients, therefore, included in the
study. For the sake of readability, treatments after the third line were not further specified
Table 1 Drug treatment in daily practice
Treatment First systemic
treatment line
(n = 125)
Second systemic
treatment line
(n = 39)
Platinum ? 5FU ? cetuximab 40 (32 %) 4 (10 %)
Other platinum-based
combination therapy
16 (13 %) 1 (3 %)
Methotrexate monotherapy 34 (27 %) 15 (38 %)
Capecitabine monotherapy 18 (14 %) 7 (18 %)
Other 17 (14 %) 12 (31 %)
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treatment, and/or hospital admission. 21 hospital stays
(4 % of total hospital stays) resulted from AEs, for a total
of 16 patients (13 %). Median duration of these hospital
stays was 8 days. Severe adverse events were observed
more often in patients receiving combination therapy than
methotrexate or capecitabine monotherapy (Table 4).
Table 2 Patient and tumor characteristics, stratified by first systemic treatment line group
Total
(n = 125)
Platinum ? 5FU
? cetuximab
(n = 40)
Platinum-based
combination
therapy (n = 16)
Methotrexate
monotherapy
(n = 34)
Capecitabine
monotherapy
(n = 18)
Other
(n = 17)
Sex, n (%)
Male 92 (74) 28 (70) 9 (56) 27 (79) 13 (72) 15 (88)
Median age 60 58 57 62 62 60
Age (years), n (%)
\65 90 (72) 33 (83) 14 (88) 21 (62) 11 (61) 11 (65)
C65 35 (28) 7 (18) 2 (13) 13 (38) 7 (39) 6 (35)
Primary tumor site, n (%)
Oropharynx 38 (30) 10 (25) 6 (38) 11 (32) 6 (33) 5 (29)
Hypopharynx 21 (17) 5 (13) 2 (13) 5 (15) 1 (6) 8 (47)
Larynx 17 (14) 5 (13) 1 (6) 9 (27) 2 (11) 0 (0)
Oral cavity 34 (27) 16 (40) 2 (13) 9 (27) 5 (28) 2 (12)
Nasopharynx 10 (8) 2 (5) 5 (31) 0 (0) 1 (6) 2 (12)
Other 5 (4) 2 (5) 0 (0) 0 (0) 3 (17) 0 (0)
Extent of disease, n (%)
Loco-regionally recurrent 58 (47) 20 (50) 6 (38) 18 (53) 9 (50) 5 (29)
Metastatic with or without
loco-regional recurrence
67 (54) 20 (50) 10 (63) 16 (47) 9 (50) 12 (71)
Location of distant metastases, n (%)
Bone(s) 18 (14) 7 (18) 5 (31) 2 (6) 2 (11) 2 (12)
Lung 54 (43) 16 (40) 7 (44) 15 (44) 6 (33) 10 (59)
Liver 15 (12) 5 (13) 5 (31) 1 (3) 1 (6) 3 (18)
Lymph nodes 24 (19) 10 (25) 3 (19) 6 (18) 2 (11) 3 (18)
Skin 13 (10) 8 (20) 1 (6) 1 (3) 2 (11) 1 (6)
Other 10 (8) 4 (10) 1 (6) 3 (9) 2 (11) 0 (0)
Comorbidity, n (%)
0 110 (88) 35 (88) 14 (88) 31 (91) 16 (89) 14 (82)
1 11 (9) 4 (10) 2 (13) 3 (9) 1 (6) 1 (6)
[1 4 (3) 1 (3) 0 (0) 0 (0) 1 (6) 2 (12)
Previous treatmentsa, n (%)
No previous treatments 11 (9) 6 (15) 2 (13) 2 (6) 0 (0) 1 (6)
Surgery(s) and or radiotherapy(s) only 73 (58) 25 (63) 8 (50) 22 (65) 8 (44) 10 (59)
Chemoradiation 37 (30) 9 (23) 6 (38) 9 (27) 8 (44) 5 (29)
Chemotherapy 3 (2) 1 (3) 0 (0) 0 (0) 1 (6) 1 (6)
Any cetuximab 3 (2) 0 (0) 0 (0) 1 (3) 1 (6) 1 (6)
Months between initial diagnosis SCCHN
and diagnosis R/M SCCHN
(mean, SD)
15.6, 17.5 14.2, 16.5 20.6, 25.1 18.8, 19.9 13.2, 7.0 17.3, 14.0
Months between diagnosis R/M SCCHN
and start first palliative systemic
therapy (mean, SD)
3.9, 6.1 4.1, 6.9 3.9, 7.6 4.0, 4.7 4.3, 8.0 2.6, 2.2
a Antitumor treatments for SCCHN before diagnosis of recurrence and/or metastasis. Treatment history was not a selection criterion for this
study
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Costs
Table 5 presents mean costs per treatment group and cost
category. Mean total costs per patient were €24,211
(±€22,432), ranging from €10,075 (±€9,891) (methotrex-
ate monotherapy) to €39,459 (±€21,149) (platinum ?
5FU ? cetuximab). Primary cost drivers are hospital stays
and drug costs.
Discussion
Relatively few (14 %) patients in the Netherlands with
R/M SCCHN received palliative systemic treatment.
Patient and treatment heterogeneity as well as small sample
size prevented us from statistically comparing treatment
costs and outcomes. The most frequently prescribed first-
line drug regimen consists of cisplatin ? 5FU ? cetux-
imab, followed by methotrexate monotherapy. In the sec-
ond systemic treatment line, methotrexate monotherapy is
the most frequently prescribed drug regimen. Treatment
with single agents is associated with fewer adverse events
than combination treatments. The choice of treatment is
hospital dependent (stratified data not presented for confi-
dentiality reasons).
A multi-country survey of 256 head and neck specialists
in France, Germany, Italy and Spain showed that 72 % of
R/M SCCHN patients were treated with first-line combi-
nation therapy: 65 % of these patients were treated with
cetuximab containing regimens and 35 % with other
Table 3 Overall survival and progression-free survival per treatment group
First systemic treatment line Overall survival, median (95 % CI) Progression-free survival, median (95 % CI)
Platinum ? 5FU ? cetuximab (n = 40) 6.7 (4.4–8.9) 4.8 (3.2–6.4)
Other platinum-based combination therapy (n = 16) 10.5 (5.8–15.1) 4.0 (3.5–4.4)
Methotrexate monotherapy (n = 34) 4.8 (3.5–6.1) 3.1 (1.9–4.3)
Capecitabine monotherapy (n = 18) 3.7 (1.4–5.9) 1.7 (1.5–1.9)
Other (n = 17) 5.7 (1.2–10.3) 1.6 (0.3–2.9)
All (n = 125) 6.0 (4.2–7.8) 3.4 (2.3–4.5)
Due to heterogeneity, possibilities for matching on baseline characteristics were limited and did not solve the issue of confounding by indication.
Therefore, survival estimates should be interpreted as descriptive of the respective treatment groups rather than measures of treatment effect
Table 4 Adverse events
First systemic
treatment regimen
Severe
adverse
events,
n (%)
Reported severe adverse events
CTC AE grade CIII, patient was hospitalized, and/or
treatment was adapted for toxicity reasons
Reported non-severe adverse events
CTC AE grade I and grade IIa
Cisplatinum
?5FU ? cetuximab
(n = 40)
19 (48 %) Anorexia, cardiac toxicity, ear and labyrinth disorder,
febrile neutropenia, hand–foot syndrome, nausea,
oral mucositis, thrombocytopenia, pneumonia, renal
toxicity and skin and subcutaneous tissue disorders
Acneiform rash, constipation, diarrhea,
dehydration, dry skin, fatigue, erythema
multiforme, hand–foot syndrome,
hypokalemia, mucositis, nausea, other skin
and subcutaneous tissue disorders, ototoxicity,
pain, papulopustular rash, pruritus, renal
disorders and vomiting
Other platinum-based
combination therapy
(n = 16)
5 (31 %) Diarrhea, febrile neutropenia, renal disorder and
vomiting
Anorexia, dysphagia, dry skin, fatigue, hand–
foot syndrome, leukopenia, nausea,
pneumonia and vomiting
Methotrexate
monotherapy
(n = 34)
5 (15 %) Liver toxicity, malaise, neutropenia, and oral
mucositis
Dysphagia, pneumonia, pain and fatigue
Capecitabine
monotherapy
(n = 18)
0 (0 %) None reported None reported
Other (n = 17) 5 (29 %) Renal disorders, cardiac disorder, fatigue and
constipation
Alopecia and nausea
a Although these adverse events were only recorded if their severity had been assessed by a physician and reported in the patient file, we could
not make a clear distinction between grade I and grade II adverse events due to non-specificity in reporting habits (reading, for example,
‘‘headache grade I/II’’ or ‘‘low-grade headache’’)
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platinum-based combination chemotherapy. Combination
treatment with cetuximab is a common first-line choice in
these countries (data published as abstract only) [19]. In the
Netherlands, head and neck cancer specialists seem to take
a more conservative approach with respect to prescribing
chemotherapy in general and platinum ? 5FU ? cetux-
imab in particular (32 % of all palliative, first line, non-
trial, systemic regimens). However, the difference could be
explained by different study designs, recall bias and pos-
sibly a preselected patient population of the head and neck
specialists in the multi-country survey. It is likely that
survey results provide less reliable information on treat-
ment allocation than medical chart review for all diagnosed
R/M SCCHN patients.
For the study population as a whole, median overall
survival from diagnosis was 6.0 months. Patients treated
with combination platinum regimens other than plati-
num ? 5FU ?cetuximab live longer, possibly due to their
lower age and a higher proportion of tumors that are rel-
atively sensitive to treatment, such as nasopharyngeal
carcinomas. Nasopharyngeal carcinomas are a distinct
subgroup known to respond differently to treatment than
SCCHN in other localizations. They constitute a relatively
favorable prognostic group [20].
Survival of 95 % CIs of patients treated with plati-
num ? 5FU ? cetuximab in Dutch daily practice (median
OS 6.7 months, 95 % CI 4.4–8.9, median PFS 4.8, 95 % CI
3.2–6.4) overlap with those from the EXTREME trial [11]
(median OS 10.1 months, 95 % CI 8.6–11.2, median PFS
5.6, 95 % CI 5.0–6.0) and a retrospective, observational
study from Portugal [21] (median OS 11 months, 95 % CI
8.7–13.3, median PFS 8, 95 % CI 6.1–9.9).
The data presented are the only published evidence on
the costs of systemically treated R/M SCCHN in the
Netherlands. Hospital stays and chemotherapeutics are the
main cost drivers. We report mean costs of management of
systemically treated R/M SCCHN of € 24,211. These costs
are considerable, yet not as high as published end-of-life
healthcare consumption for various cancers in a US study
population (inpatient and outpatient costs $70,956, in 2009
USD) [22]. For the Netherlands, mean costs of late stage
cancer management have not been explored in great detail.
Costs incurred for cancer care do not automatically
result in better outcomes [23]. Policy makers, oncologists
and public media increasingly express the need to curtail
the rise in costs of cancer care. Suggested changes include
limiting the use of chemotherapy combination regimens for
metastatic cancers and limiting chemotherapy on the basis
of performance status [24]. Even disregarding the costs,
extensive use of chemotherapy at the end of life can be an
important signal of poor quality care [25]. Our study shows
relatively few R/M SCCHN patients to receive systemic
palliative treatment, which might reflect careful patient
selection due to the small expected gains of such treat-
ments, considerable toxicity and high costs.
Still the presented cost estimates raise the question about
the value for money that is achieved. Very little is known
about this for the R/M SCCHN patient population. There is
relatively little high-quality research in these patients,
possibly due to rarity of the disease in western countries,
heterogeneity within the patient population (amongst oth-
ers in tumor localization), lack of new treatment com-
pounds, and difficulties associated with quality of life
measurements in end stage cancer patients. To our
knowledge, no pharmacoeconomic studies have been
published about systemic R/M SCCHN treatments except
for cost-effectiveness studies regarding platinum ? 5FU ?
cetuximab versus platinum ? 5FU [26, 27].
Analysis of the cost-effectiveness of systemic treatments
in daily practice requires information about (changes in)
health-related quality of life and a large enough patient
population to compare treatment strategies while correcting
for confounding by indication. Preferably these data should
be collected within a population-based patient registry,
including all newly diagnosed patients with head and neck
SCC in the Netherlands. Such a register has the potential to
boost the quality of head and neck cancer research and has
a reasonable feasibility in the Netherlands due to the cen-
tralized nature of head and neck cancer care. However,
several challenges exist regarding patient identification as
well as patient follow-up in the terminal phase.
Limitations of the study
Squamous cell carcinoma of the head and neck patients
form a relatively small and heterogeneous population. This
limited possibilities to correct for confounding by indica-
tion. As a result the effect of treatment choice on outcomes
could not be assessed and only descriptive results were
presented.
Furthermore, the level of detail in medical records var-
ied greatly. This prevented uniform capture of several
variables, such as performance status and adverse events.
For example, the lack of adverse events seen in patients
receiving capecitabine monotherapy could be due to a less
intensive follow-up since this treatment is self-adminis-
tered at home. The lack of certain anticipated adverse
events, such as hypomagnesaemia with the platinum-based
treatments, results from the data managers recording AEs
only when explicitly reported by clinicians, without, for
example, consulting laboratory values themselves.
Notably, our research was conducted in patients identi-
fied through hospital records and focused on treatment in a
specialized head and neck center setting. Some 90 % of
SCCHN patients in the Netherlands visit these head and
neck centers [14]. However, patients who do not seek
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specialized medical care were not included in this study.
Therefore, the proportion of patients not receiving systemic
therapy is likely to be underestimated. Furthermore, two
out of eight head and neck centers did not participate in the
study and might have had different treatment patterns.
Also, hospital and pharmacy databases can be incomplete,
especially when patients had only few hospital contacts.
Resource consumption of interventions offered outside
the study hospital, i.e. for patients referred to other (out-
patient) clinics for drug administration, was not recorded.
Therefore, presented cost estimates reflect the costs
incurred within the head and neck treatment centers. Cost
utility of treatments for R/M SCCHN could not be assessed
due to a lack of comprehensive outcomes reporting, spe-
cifically on quality of life.
Conclusion
For systemically treated patients with R/M SCCHN, health
care utilization and associated costs are considerable, while
the survival is limited.
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